News & Updates
Filter by Specialty:
CDK4/6 inhibitors + fulvestrant improve OS in HR-positive, HER2-negative advanced breast cancer
The addition of a cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor to fulvestrant provides a consistent benefit in overall survival (OS) in patients with hormone receptor (HR)–positive, HER2-negative, advanced or metastatic breast cancer in first-, second- and later-line settings and in most clinicopathological subgroups of interest, results of a US FDA pooled analysis of have shown.
CDK4/6 inhibitors + fulvestrant improve OS in HR-positive, HER2-negative advanced breast cancer
18 Oct 2021
Lenalidomide plus R-CHOP effective for untreated DLBCL patients
Combining lenalidomide with R-CHOP* (R2CHOP) yields durable and high rates of treatment response in untreated patient with diffuse large B-cell lymphoma (DLBCL), a recent study has found.
Lenalidomide plus R-CHOP effective for untreated DLBCL patients
16 Oct 2021
Second-line selective internal radiotherapy slows colorectal liver metastases progression
Administering a device-based selective internal radiation therapy, in addition to systemic treatment in the second-line setting, extends time to progression in colorectal liver metastases patients, as shown in the phase III EPOCH trial.
Second-line selective internal radiotherapy slows colorectal liver metastases progression
14 Oct 2021
KEYNOTE unlocks immunotherapy OS benefit in metastatic TNBC, effective in early disease
Triple-negative breast cancer (TNBC) is considered one of the highest-risk subtypes of breast cancer and has a dismal prognosis. However, immunotherapy survival benefits reported in KEYNOTE-522 and KEYNOTE-355 trials bring new hope for this indication. [Ann Oncol 2021;32:994-1004]
KEYNOTE unlocks immunotherapy OS benefit in metastatic TNBC, effective in early disease
14 Oct 2021
Gene mutations may provide clues for liver cancer survival
Recent research has found that mutations in the human EZH2 and CCND1 genes may be potential novel biomarkers for liver cancer. The tumour mutation burden (TMB) also appears to be an important prognostic factor and affects patient survival.
Gene mutations may provide clues for liver cancer survival
13 Oct 2021
Rituximab suppresses anti-S COVID-19 antibodies in patients with haematological malignancies
While patients with haematological malignancies (HM) are able to mount a persistent antibody response against the spike (S) protein of the SARS-CoV-2 virus, early treatment with rituximab completely abolishes such response, a recent study has found. These findings could help inform coronavirus disease 2019 (COVID-19) vaccination policies for patients with HMs.